FDA+ roundup: FDA's neu­ro­science deputy de­parts amid on­go­ing Aduhelm in­ves­ti­ga­tions; Califf on the ropes?

Amid in­creased scruti­ny in­to the close ties be­tween FDA and Bio­gen pri­or to the con­tro­ver­sial ac­cel­er­at­ed ap­proval of Aduhelm, the deputy di­rec­tor of the FDA’s of­fice of neu­ro­science has called it quits af­ter more than two decades at the agency.

Er­ic Bast­ings will now take over as VP of de­vel­op­ment strat­e­gy at Io­n­is Phar­ma­ceu­ti­cals, the com­pa­ny said Wednes­day, where he will pro­vide se­nior clin­i­cal and reg­u­la­to­ry lead­er­ship in sup­port of Io­n­is’ pipeline.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA